Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00730262
Other study ID # TLN-4601-201
Secondary ID
Status Terminated
Phase Phase 2
First received August 6, 2008
Last updated December 29, 2009
Start date August 2008
Est. completion date June 2010

Study information

Verified date December 2009
Source Thallion Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.


Recruitment information / eligibility

Status Terminated
Enrollment 40
Est. completion date June 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed Glioblastoma Multiforme (GBM)

- Prior treatment with radiation and one first line systemic therapy (including temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination therapies), followed by measurable and unequivocal evidence of tumor progression or recurrence

- Age = 18 years

- ECOG = 2

- Normal organ and marrow function as defined below:

- leukocytes =3 x 109/L

- absolute neutrophil count =1.5 x 109/L

- platelets =100 x 109/L

- hemoglobin =90 g/L

- total bilirubin =2.5 X institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) =2.5 X institutional upper limit of normal

- creatinine =1.0 X institutional upper limit of normal

Exclusion Criteria:

- Patients with a life expectancy < 12 weeks

- Patients with a documented history of HIV, active hepatitis B or C infections

- Female patients who are pregnant or lactating

- Patients in whom a proper central line (Portacath-like device) cannot be established

- Patients with a known hypersensitivity to farnesylated dibenzodiazepinone or polysorbate 80

- Patients with uncontrolled hypotension

- Patients with concomitant therapy of therapeutic coumadin

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TLN-4601
14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period

Locations

Country Name City State
Canada Hôpital Notre-Dame du CHUM Montreal Quebec
Canada Royal Victoria Hospital Montreal Quebec
Canada Ottawa Health Research Institute Ottawa Ontario
Canada L'Hotel-Dieu de Quebec Quebec
Canada Centre Hospitalier Universitaire de Sherbrooke Sherbrooke Quebec
Canada The Pencer Brain Tumor Center, Princess Margaret Hospital Toronto Ontario
United States Duke University Durham North Carolina
United States Sloan-Kettering Institute for Cancer Research New York New York

Sponsors (1)

Lead Sponsor Collaborator
Thallion Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the efficacy of TLN-4601 in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1). 6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1)
Secondary To examine the safety and tolerability of TLN-4601 in patients with recurrent GBM Maximum 13 months from date of initial infusion of TLN-4601 (Day 1, Cycle 1)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Recruiting NCT06059690 - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Phase 1/Phase 2
Recruiting NCT04116411 - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Phase 2
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Completed NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Recruiting NCT01923922 - CT Perfusion in the Prognostication of Cerebral High Grade Glioma N/A
Completed NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma Phase 1
Completed NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. Phase 1/Phase 2
Suspended NCT01386710 - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Phase 1/Phase 2
Completed NCT01402063 - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Phase 2
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Terminated NCT00990496 - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) Phase 1
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00402116 - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase 1/Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Recruiting NCT05366179 - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc Phase 1